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Summary 
We have investigated the impact of mutations on the binding functions of the phosphocholine 
(PC)-speciiic T15 antibody in the absence of antigen selection pressure. The H chain complementarity 
determining region 2 (CDR2) sequence of T15 antibody was saturated with point mutations 
by in vitro random mutagenesis. From the mutant library,  289 clones were screened by direct 
DNA sequencing. The point mutations generated by this method were randomly distributed 
throughout the CDR2 region and included all kinds of substitutions. 46 unique mutant antibodies, 
containing one to four point mutations each, were expressed in SP2/0 myeloma cells. Functional 
analysis on these antibodies has provided insights into several aspects of somatic mutation. (a) 
The majority (26/46) of mutant antibodies either lost (20/46) or had reduced (6/46) ability 
to bind PC-protein conjugates or R36a, a PC-expressing strain of Streptococcus pneumoniae.  In 
contrast, none of the mutant antibodies displayed increased binding for these PC antigens. Taken 
together with calculations  of destructive mutations elsewhere in the V region, the data suggest 
that somatic mutation may cause extensive wastage among B cells during clonal expansion after 
antigen stimulation. (b) The frequency of binding-loss mutants increased sharply when a second 
mutation was introduced into the CDR2 sequence; it appears that, in some cases, two or more 
mutations are needed to destroy binding. (c) The mutant antibodies were tested for their reactivity 
to 11 non-PC antigens as well as to three PC analogues. None of the mutants gained new reactivity 
or changed their ability to discriminate structural analogues,  supporting the notion that the 
major role of somatic mutation is to increase or decrease aff~ty rather than to create new specificities. 
(d) Mutations in at least five different positions in CDR2 were deleterious, suggesting that these 
residues  may be essential for antigen binding. Three of these positions are novel in that they 
had not been identified to be important for binding PC by previous crystallographic analysis. 
(e) Introduction of mutations into two highly conserved residues in CDR2 did not alter the 
overall conformation of the V region as judged by antiidiotypic analysis, and, in some cases, 
did not affect the antigen binding function. The results thus indicate that even nonconservative 
substitutions of invariant residues need not be deleterious,  suggesting that their conservation 
may be due to reasons other than maintaining antibody structure or specificity. 
I 
n the course of an antigen-specific immune response,  so- 
matic mutations accumulate in antibody V region genes 
and their immediate flanking sequences at an extraordinarily 
high rate (~10-3/bp/generation) (1-4). Subsequent selection 
by the antigen of B cells expressing higher affinity antibodies 
frequently results in "affinity maturation" of the antibody 
pool (5). It is generally assumed that mutations occur ran- 
domly over the length of the V region (6), although recent 
studies have suggested that there may be mutational hot spots 
(3, 7, 8). The mechanism of somatic hypermutation is un- 
known, and its impact on the structure and function of anti- 
bodies is not well understood. Studies have been hampered 
by the lack of in vitro experimental systems. Antibodies re- 
covered during an immune response have been subjected to 
selective pressures  and thus may not provide an unbiased 
representation of the entire range of somatic mutational prod- 
ucts.  For example,  the fraction of mutations leading to a 
non-antigen-binding antibody or to a structurally nonfunc- 
tional antibody is not known because antibodies having these 
mutations are seldom recoverable. Efforts have been made to 
recover such mutants either by antiidiotypic stimulation of 
B cells previously primed with antigen (9) or by molecular 
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quently used by antiarsonate antibodies (10). Several mutants 
with drastically reduced or undetectable binding for the im- 
munizing antigen were isolated (9, 10), indicating that such 
deleterious mutations do occur in vivo. Another useful ap- 
proach to obtain loss mutants has been to screen for sponta- 
neous variants  from cultured  cell lines  (11-14).  These  ap- 
proaches, although providing important  information about 
the effects of somatic mutation on antibody specificity,  suffer 
from the inherent problem of low efficiency in the detection 
and recovery of such mutants  (9,  15). 
It is not clear why mutations  accumulate in some V  re- 
gion genes less frequently than in others even when the B 
cells  expressing them are induced by the same antigen  (3, 
16-18). One interpretation  is that mutations in the CDRs 
of some genes might lead to antigen-binding  loss mutants 
more frequently than in others; alternatively, different muta- 
tional rates may be exerted on different genes. 
An experimental approach to generate random point mu- 
tations in V region sequences was used to address these ques- 
tions. This approach utilizes automated DNA synthesis and 
allows rapid generation of a point mutation library that con- 
tains  all the possible base substitutions in a defined target 
sequence. The heavy chain CDR2 sequence of the T15 an- 
tiphosphocholine  (anti-PC) 1 antibody  was  chosen  as  the 
target because the high-resolution crystal structure of a closely 
related anti-PC antibody McPC603 (19-21) is available,  and 
a model of the T15 antibody was established based on the 
McPC603 structure (13). Thus, it is possible to analyze the 
significance of particular  mutations  at  the structural  level. 
Furthermore,  unmutated  T15  antibodies  exhibit  optimal 
binding to Streptococcuspneumoniae,  which expresses a carbo- 
hydrate-linked form of PC, and mutations in T15 usually result 
in decreased binding (21). Even in the response to PC-protein, 
mutated T15 antibodies have displayed only moderately in- 
creased hapten binding (less than twofold) (6). In contrast, 
non-T15 anti-PC antibodies display a high degree of somatic 
mutation concentrated in CDR regions (especially heavy chain 
CDR2),  and mutations  have usually caused an increase in 
affinity (6, 22-24).  Thus,  it was of considerable interest to 
test if T15 antibodies are particularly susceptible to somatic 
changes that  result in loss of function. 
Mutations covering every nucleotide position were randomly 
introduced into the V, CDR2. The resultant mutants were 
analyzed for their antigen binding specificity.  The results re- 
veal several important features of the randomly mutated an- 
tibodies as well as the functional importance  of individual 
residues. 
Materials and Methods 
Plasmids and Vectors.  The pTZ18U phagemid was obtained from 
Bio-Rad Laboratories (Richmond,  CA). The genomic clone of the 
$107 V. region  gene and  the pSV2neoVg22CK construct were 
kindly provided by Dr. S. L. Morrison  (University of California, 
Los Angeles, CA) (25). The pSV2gptS1073~2b vector was con- 
1 Abbreviations used in this  paper: GPC, t-oe-glycerophosphocholine;  NPPC, 
p-nitrophenyl phosphocholine; PC, phosphocholine. 
structed  by inserting  the S107 (T15) V.  region  gene  into  the 
pSV2gpt3,2b plasmid (Fig. 1), which was a kind gift from Dr. J. 
Sharon (Boston University  School of Medicine) (26) and which 
has been engineered in our laboratory as described previously (27). 
Synthesis of Mutant Oligonucleotides.  Synthesis was performed 
in Dr. J. p. Adelman's laboratory (Oregon Health Sciences Univer- 
sity) in a DNA synthesizer (391; Applied Biosystems, Inc., Foster 
City, CA).  The total length of the oligo is 75 nucleotides with 
the central 57 nucleotides being randomly substituted while leaving 
nine unmutated nudeotides at each end. Standard synthesis proce- 
dures were used except that each of the four parental nucleotides 
was doped with 3% of each of the three "mutant" nudeotides to 
give rise to a maximum yield of double mutations  in the target 
sequence  (28). The  oligonucleotides  were  purified  and  phos- 
phorylated  by standard methods (29). 
Generation of Mutant Library.  Mutagenesis was performed ac- 
cording to the instruction  manual of the Muta-Gene kit (Bio-Rad 
Laboratories) as depicted in Fig. 1. Briefly, the mixture of mutant 
oligonucleotides  was  hybridized  to  the  single-stranded,  uracil- 
containing  pTZ18US107 plasmid that contains the genomic $107 
VH region gene. The complementary  strands were then  synthe- 
sized by T4 DNA polymerase using the oligonucleotide as primer. 
Ligase was added to seal the new strand to the 5' end of the oligo. 
The double-stranded  DNA was transformed  into Escherichia coli 
XL-1 blue strain, which has functional  uracil N-glycosylase and 
thus selects against the uracil-containing parental strand. The trans- 
formants  were stored as a mutant library at 4~ 
DNA Sequencing.  Sequencing was performed as described in 
the instruction  manual of the UBA sequenase kit (United States 
Biochemical Corp., Cleveland, OH) using double-stranded plasmid 
DNA as template. A 17-nucleotide primer, 5' TTCATCTGAAGG- 
TAGAG 3" complementary to the framework 3 region of the $107 
V.  gene, was used  to sequence the  CDR2  mutations.  A JH1 
primer, 5' GAGGAAACGGTGACCGT  Y, plus the above frame- 
work 3 primer were used to sequence the entire $107 V. region. 
The complete V region of each of the mutants was sequenced after 
introduction  into the pSV2 expression vector to ensure that no 
other changes were introduced  in addition to the desired CDR2 
mutations. 
Cell Culture and Transfection.  SP2/0 myeloma cells were cultured 
in IMDM plus  20%  FCS. Transfection was performed  by the 
lipofectin method as described previously (27). Briefly, cells were 
grown in six-weU tissue culture plates to "~50% confluence and 
transfected with 10 #g DNA plus 30 #1 lipofectin (Bethesda Re- 
search Laboratories, Gaithersburg, MD). After 24 h, selection drugs 
(see below) were added and the cells were transferred to a 96-well 
plate. Stable transfectants could be seen microscopically in ,,,7 d 
and the supematants screened for antibody in '~2 wk. Usually 10-20 
drug-resistant  transfectants were obtained from each transfection 
and three clones that secreted antibody were saved for further anal- 
ysis. Transfection was done in either of two ways: (a) cotransfec- 
tion of pSV2neoVg22CK  and pSV2gptS107 DNA and selection with 
G418  (1  mg/ml);  (b)  SP2/0  cells were  first  transfected  with 
pSV2neoVK22CK and selected with G418; the stable transfectant 
of SP2/0-Vlc22CK was then  transfected with pSV2gptS107 and 
selected with mycophenolic acid (30). 
Antibody Purification.  Antibody secreted by transfectants  was 
purified from tissue culture supernatants by affinity chromatog- 
raphy on either PC-Sepharose 4B or protein  A-Sepharose CL-4B 
(Pharmacia, Uppsala, Sweden) as described previously (27, 31). 
ELISA.  Direct binding  and solid phase inhibition  ELISA as 
well as the various antigens used were described previously (32). 
Supernatants  from 96-well plates were first screened with  goat 
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sociates, Birmingham, AL), and PC-histone. Transfected cells that 
secreted approximately the same amount of 3' and r chains were 
expanded and saved. Binding to R36a, PC-histone, PC-BSA, and 
PC-KLH was tested by direct binding ELISA (31, 32) with various 
concentrations of affinity-purified antibody. Expression of the T15 
idiotype was tested with two anti-T15 antibodies. Goat anti-T15 
antiserum was kindly provided by Dr. J. Kenny (National Cancer 
Institute,  Frederick, MD). This antiserum is specific for T15 V. 
and VL regions, and its binding can be inhibited by PC-BSA but 
not by free PC or BSA as tested in this laboratory, mAb B36-82 
(3'1, K) (33, 34) was a kind gift from Dr. J. Cerny (University of 
Maryland, Baltimore, MD) and also reacts with T15 V,-Vr. The 
recognition  of T15 by B36-82 is not inhibited by free PC and is 
only marginally inhibited by PC-BSA (34, 35). Purified anti-T15 
antibody was coated on the plates and then overlaid with purified 
mutant T15 antibodies at 100 ng/ml. Binding was detected by fur- 
ther incubation with rabbit anti-mouse "~2b antibody coupled to 
alkaline phosphatase and developed  with the substrate, nitrophenyl 
phosphate. Wells receiving  buffer instead of T15 antibody were used 
as blanks. Mutant antibodies were also tested for binding to var- 
ious PC-unrelated antigens, including BSA, histone, KLH, albumin, 
ubiquitin,  actin, FITC-BSA, DNP-BSA, oxazolone-BSA, soman- 
BSA, and DNA as described  previously  (32). To maximize our ability 
to detect anti-DNA activity, single-stranded DNA (ssDNA) was 
used in the binding tests since, except in a few cases (12, 36), most 
DNA-reactive antibodies have  been shown to bind ssDNA (36-38), 
whereas a considerable proportion of the latter do not bind dsDNA 
(36-38).  The Is0 values for the inhibitors PC, p-nitrophenyl  PC 
(NPPC), r<~-glycero-PC (GPC), and choline were determined as 
detailed previously (32). 
R~StlIts 
Generation of the TI5 H Chain CDR2 Mutant Library.  Oli- 
gonucleotides encoding the CDK2 of T15 (S107) V, region 
were synthesized with random incorporation of point muta- 
tions and annealed to the wild-type S107 V,1 gene present 
in the pTZ vector (Fig. 1). After strand extension, the pTZ/S107 
constructs  were transformed into  the XD1  blue strain of 
E. coli to produce a mutant library. Mutations were deter- 
mined by direct sequencing of individual transformants. 76 
of 289 dones sequenced had point mutations and retained 
the correct reading frame. Out of the 76 clones, 12 had stop 
codons, seven had silent mutations,  and 57 had mutations 
that caused amino acid substitutions. As listed in Fig. 2, there 
were 51 unique mutants:  18 have a single substitution,  13 
have two, 10 have three, nine have four, and one has five sub- 
stitutions. The mutations are randomly distributed throughout 
the whole CDR2 region, and every position has at least two 
different amino acid substitutions. There is a total of 115 sub- 
stitutions representing 19 different amino acids. Tryptophan 
was not found as a substitution and is not present in the germ- 
line H  chain CDR2 of $107. 
Binding of  Mutant Antibodies to R36a and PC-Protein.  Wild- 
type and 46 of the mutated $107 V, region genes shown in 
Fig.  2 were linked to the mouse 3'~b constant region gene 
(Fig. 1) and expressed in SP2/0 myeloma cells (SP2/0 itsdf 
does not express mature H  or L chains) together with germ- 
line Vr22Cr L chain gene. Transfectants expressing both V, 
$107 and Vr22 were selected and their binding features ana- 
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Figure 1.  Strategy  of  random mutagenesis  and transfection.  The whole 
V. CDK2 sequence  (57 nucleotides)  of the T15 antibody  was synthesized 
in a DNA synthesizer. During automated synthesis, random mutations 
were introduced  into the DNA by "doping"  each  of the four dNTP with 
3% each of the other three. The synthetic  mutant oligonucleotides  were 
annealed to the single-stranded, uracil-containing  pTZ18US107  phagemid, 
which contains the wild-type $107 V. gene. The complementary  strand 
was then extended  with DNA polymerase  using the oligo as primer. The 
mutant pTZS107  phagemids  were  transformed  into E. coli  XI.,1  blue  strain, 
which was able to select against the uracil-containing  wild-type strand; 
the transformants  were saved  as a mutant library. Individual  transformants 
from the library  were sequenced  to determine  the mutations. The mutant 
variable region genes  were removed  from the pTZ18U  vector  and inserted 
into a mammalian expression  vector,  pSV2gpt, which carried  a mouse Ig 
3'~ constant region  gene. The pSV2gptS107 construct  was transfected  into 
the myeloma  cell  line  SP2/0  together  with a mouse  Vx22Cr L chain  gene, 
which had been  cloned  into the pSV2neo  vector.  K1, EcoKI;  B1, BamHI. 
The various gene segments are not drawn to scale. 
lyzed. Purified antibodies at various concentrations were tested 
for binding to S. tmeumoniae R36a and to PC-protein. In R36a, 
PC  is linked  to  the bacterial cell wall polysaccharides via 
teichoic acid. Fig. 3 shows the results for several representa- 
tive antibodies  that  have comparable (M20,  M67),  lower 
(M135, M296), or undetectable (M28, Ml11) binding to R36a 
and PC-histone as compared to wild-type T15 antibody. In 
addition to R36a and PC-histone, all 46 mutant antibodies 
were also examined for binding to two other PC-protein con- 
jugates, PC-KLH and PC-BSA, and the results were corn- 
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WT  ASRNKANDYTTEYSASVKG  0 
M20  -  ..............  P  -  -  -  i 
M22  T  ...............  L  2 
M28  .....  S  .......  R  -  T  -  T  -  4 
M32  -  -  -  K  .........  R  .....  2 
M34  -  -  K  -  ...........  P  -  N  -  3 
M41  ................  H  1 
M54  .....  T  -  -  -  .....  P  -  G  -  Z  4 
M66  ..................  $  1 
M67  ................  F  -  -  1 
M72  ................  A  1 
M85  2  --I  ....  -H  .......... 
M102"  ........  Y  A  P  Q  -  -  -  T  -  -  -  5 
M106  -  -  -  C  -  -  K  ...........  R  3 
MI07  .................. 
MII3  ..................  D  1 
M127  ..........  A  ........  1 
M134"  .................  N  D  2 
M135  ......  S  ............  1 
M142  .......  V  ...........  1 
M143  ..........  R  Q  -  -  -  p  -  N  -  4 
M145  _  L  .....  H  -  -  -  Q  ....  G  -  3 
M148  .............  I  .....  1 
MI50  ................  E  -  -  1 
M152  -  -  S  ....  V  ...........  2 
M154  .................  K  I  2 
M159  .............  G  -  -  M  R  -  3 
MI60  ........  H  -  -  -  -  R  .....  2 
MI61  ..................  Q  1 
M164  -  -  I  .........  $  ......  2 
M166  -  -  -  K  .......  G  -  -  -  Y  M  -  -  4 
MI71  G  T  ...............  2 
M173  ......  T  ............  1 
M175  ........  H  $  .....  2 
M183  ....  E  ......  Q s  -  -  ~  ~  2  2  4 
M201*  ..................  g  1 
M205  -  -  -  D  .......  A  -  -  -  -  N  -  -  3 
M229  G  ................  P  2 
M248  ............  D  ....  N  -  2 
M241  -  R  .....  E  ....  S  ......  3 
M242  -  -  S  -  -  V  .......  K  .....  3 
M244  -  -  -  T  .........  R  ....  A  3 
M255  ....  Q  -  -  -  F  -  -  V  -  -  -  -  ~  M  -  4 
M257  ......  K  Y  -  K  ......  R  4 
M260  Q  C  -  -  L  .........  T  -  -  -  4 
M275"  -  -  K  ...............  1 
M276  -  G  ..........  R  ....  2 
M289  .....  V  S  E  ...........  3 
M296  -  I  .................  1 
M306'  -  C  .................  1 
Figure 2.  Amino acid sequences of the wild-type (germline) and mu- 
tant $107 CDR2 regions. The wildtype (WT) sequence is shown on the 
top with the single-letter code.  Mutant clone names are shown on the 
left.  The number of" substitutions  in each clone is shown on the right. 
Substitutions are indicated by single-letter code, and a dash indicates se- 
quence identity. The distribution of mutations is random throughout the 
CDR2 region according to X  2 analysis (X  2 -19.82, df=18, p >0.25). Mu- 
tants with an asterisk are not included in further analysis due to failure 
of transfection. 
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Figure 3.  Binding of wild-type and mutant T15 antibodies to carbohy- 
drate (A) and protein (B) conjugated forms of PC. Afflnlty-purified anti- 
bodies at various concentrations were tested by ELISA for binding to R36a 
(A) and t'C-histone  (/3). Each OD40s point represents the mean of tripli- 
cate determinations. 
parable to those for PC-histone  (data not shown). Binding 
activity was calculated based on the concentration  of anti- 
body that gave an OD value of 0.5 in ELISA. Mutant anti- 
bodies that differed from wild-type by more than threefold 
were considered to have decreased or increased binding  ac- 
tivity.  As shown in Table 1, 20 antibodies (43%) lost their 
ability to bind R36a; of these 20, 17 (37%) also lost the ability 
to bind PC-protein.  In addition,  six antibodies (14%) had 
decreased binding for R36a and seven antibodies (15%) had 
decreased binding for PC-protein. Thus, the majority of mu- 
tant antibodies either lost or had decreased binding, particu- 
larly for the carbohydrate form of PC present in R36a, which 
is commonly perceived as the environmentally important form 
of PC-antigen  (39).  In contrast,  none of the mutant  anti- 
bodies displayed increased binding activity and only 20 mu- 
tant antibodies retained binding to R36a and PC-protein that 
was comparable to wild type. 
The correlation of loss of binding with the level of muta- 
tion was analyzed to determine whether the frequency of non- 
binding mutants would increase as the level of mutation in- 
creased. Table 2 lists the percentage of nonbinding  mutants 
containing one to four mutations. Only 1 of 15 mutant anti- 
bodies lost the ability to bind PC among those that had a 
single  substitution.  Loss of binding increased dramatically 
to "~50% when two, three, or four mutations were present. 
As a consequence of random mutagenesis,  most of the 15 
single mutations  were unique  and did not appear in other 
mutant antibodies. However,  four of them, Ser62--,-Pro in 
M20, Asn-53-~Ser in MD5, Asp-54~Val in M142, and G1u- 
58-~G1n in M161, did occur in antibodies with mnltiple mu- 
tations. Two of the four, M20 and M142, had muhi-mutated 
counterparts (M34 and M152) that lost PC binding  ability. 
This suggests that the increase in nonbinding mutants having 
two or more mutations may partly be a consequence of cooper- 
ative effects between different mutations. 
Recognition of  Mutant Antibodies by Antiidior2tpic  Reagen~  To 
investigate whether the loss of binding was due to major con- 
formational changes in the antibody combining site, expres- 
sion of the T15 idiotype by the mutant antibodies was tested 
with a polyclonal anti-T15 antiserum and the anti-T15 mAb 
B36-82 (33, 34). These antiidiotypic antibodies (anti-Id) recog- 
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Mutant Antibodies 
Recognition by 
Binding activity*  anti-T15* 
Mutant#  R36a  PC-histone  Antiserum  B36-82 
% 
S107 wt  100  100  +  +  +  +  +  + 
M22  0 II  0  +  +  +  + 
M28  0  0  +  +  +  +  +  + 
M34  0  0  +++  +++ 
M54  0  0  +  +  +  +  + 
M66  0  0  +  +  +  +  +  + 
M85  0  0  +  +  +  +  +  + 
Mlll  0  0  +  +  +  +  +  + 
M152  0  0  +  +  +  +  +  + 
M153  0  0  +  +  +  +  +  + 
M154  0  0  +  +  +  +  +  + 
M164  0  0  +  +  +  +  +  + 
M166  0  0  +  +  +  +  +  + 
M171  0  0  +  +  +  +  +  + 
M229  0  0  +  +  +  +  +  + 
M241  0  0  +  +  +  +  +  + 
M242  0  0  +  +  +  +  +  + 
M260  0  0  +  +  +  +  +  + 
M32  0  12  +  +  +  +  +  + 
M106  0  7  +  +  +  +  +  + 
M183  0  58  +  +  +  +  +  + 
M135  10  27  +++  +++ 
M173  7  39  +  +  +  +  +  + 
M244  9  29  +  +  +  +  +  + 
M289  12  31  +++  +++ 
M296  14  19  +  +  +  + 
M41  16  20  +  +  +  +  +  + 
M20  74  100  +  +  +  +  +  + 
continued 
nize epitopes  that are close to the antigen-binding site and 
require the presence of both the T15  H  and L  chain variable 
regions (35, 40). As shown in Table 1, all of the mutant anti- 
bodies were  able to  react  with  both  antiidiotypic reagents 
to approximatdy  the same degree as the parental T15  anti- 
body.  The  only exception is M22,  which  showed a  weaker 
reactivity to B36-82 than to the wild-type antibody.  These 
results suggest that there is little alteration in the overall con- 
formation  of the V  regions  of these mutant  antibodies. 
Reactivity with PC Analogues and PC-unrelated Antigens.  To 
test whether the H  chain CDR2  mutations have an influence 
on fine specificity, the mutants that retained binding activity 
were  examined for  their  ability to bind PC,  NPPC,  GPC, 
and choline.  NPPC  resembles PC  when  it is coupled  to  a 
Table  1.  (continued) 
Binding activity* 
Recognition by 
anti-T15t 
MutantsS  R36a  PC-histone  Antiserum  B36-82 
M67  57  65  +  +  +  +  +  + 
M72  52  63  +  +  +  +  +  + 
M107  71  77  +++  +++ 
Ml13  73  58  +  +  +  +  +  + 
M127  114  114  +  +  +  +  +  + 
M142  77  76  +++  +++ 
M143  57  78  +++  +++ 
M145  46  34  +  +  +  +  +  + 
M148  50  57  +++  +++ 
M150  64  73  +  +  +  +  +  + 
M159  117  160  +  +  +  +  +  + 
M160  59  50  +  +  +  +  +  + 
M161  78  126  +  +  +  +  +  + 
M175  47  74  +++  +++ 
M205  161  160  +  +  +  +  +  + 
M240  40  44  ++  +  ++  + 
M255  117  110  +  +  +  +  +  + 
M257  109  126  +  +  +  +  +  + 
M276  42  58  +++  +++ 
~ Binding activity was calculated based on the antibody concentration 
(ng/ml) that gives an OD of 0.5 in ELISA:  binding activity  =  100 x 
(WT conc. giving OD 0.5/mutant conc. giving OD 0.5). Those bind- 
ing activity values  that show a threefold difference  from the wildtype 
T15 antibody are highlighted in boldface print. 
* Binding to various anti-T15 antibodies was tested by direct-binding 
ELISA as described in Materials and Methods. Purified antibodies were 
added to the anti-T15-coated plates at a concentration of 100 ng/rrd. The 
OD readings of triplicates were averaged and are expressed in a simplified 
scale:  +  +  +  >0.8;  +  +  =  0.2-0.8;  +  =  0.01-0.2. 
$ The T15 wild-type and VH CDR2 mutant antibodies are all IgG2b 
and were expressed in myeloma cell line SP2/0, which had been cotrans- 
fected with the wild-type V~22 light chain gene.  The corresponding 
CDP,2  sequences  for these antibodies are shown in Fig.  2. 
]l These antibodies gave no binding at concentrations of 2,000 ng/ml. 
Table  2.  Correlation between the Level of Mutation in CDR2 
and the Frequency of Occurrence of Nonbinding Antibodies 
No.  of  No.  of  No.  of  Percent of 
mutations  antibodies  nonbinders  nonbinders 
1  15  1  6.7 
2  12  7  58 
3  10  4  40 
4  9  5  56 
859  Chen et al. Table  3.  Fine Specificity of the T15  Vu CDR2 Mutants 
that Retain Binding Activity for PC Protein 
Is0 (10 -s M)* 
Mutants*  PC  NPPC  GPC  Choline 
to bind to 11 different non-PC antigens, including BSA, his- 
tone, KLH, albumin, ubiquitin, actin, ssDNA, DNP-BSA, 
FITC-BSA, oxazolone-BSA, and soman-BSA.  None of the 
mutant antibodies showed detectable reactivity to any of these 
antigens (data not shown). 
Wildtype  0.08  0.36  0.43  62 
M20  0.05  0.30  0.26  42 
M41  0.10  0.73  0.85  78 
M67  0.06  0.25  0.18  40 
M72  0.07  0.43  0.29  63 
M107  0.09  0.58  0.68  81 
Ml13  0.07  0.78  0.17  57 
M127  0.13  0.65  0.74  71 
M135  0.06  0.22  0.16  18 
M142  0.22  1.74  0.97  179 
M143  0.07  0.86  0.76  120 
M145  0.48  8.65  7.74  630 
M148  0.08  0.17  0.62  81 
M150  0.05  0.28  0.46  39 
M159  0.09  0.31  0.89  50 
M160  0.09  1.19  0.70  83 
M161  0.09  0.97  0.91  144 
M173  0.12  0.48  0.13  31 
M175  0.08  0.52  0.37  76 
M205  0.08  0.16  0.23  33 
M240  0.09  0.11  0.82  80 
M244  0.21  0.47  1.34  50 
M255  0.06  0.23  0.17  34 
M257  0.11  0.96  0.88  123 
M276  0.10  0.55  0.35  69 
M289  0.07  0.26  0.38  23 
M296  0.07  1.00  0.72  62 
* The Is0 value  is defined  as the concentration  (10 -5 M) of the haptens 
required to inhibit by 50% the binding of antibody  to PC histone-coat- 
ed plates. Each sample was tested two to three times; the differences  in 
Is0 values between tests were less than twofold. The mean values are 
shown. 
* Only antibodies that bound to both R36a and PC protein are shown. 
protein via diazophenyl linkage, whereas GPC more closely 
resembles PC-polysaccharide. Binding to various hapten an- 
alogues was examined by inhibition ELISA.  Is0 values are 
summarized in Table 3.  All mutant antibodies that bound 
R36a and PC-protein also retained their ability to bind the 
PC analogues. Moreover, the overall fine specificity patterns 
of mutant antibodies as determined by Is0 values were similar 
to that of the wild type, namely, lowest Is0 for PC, inter- 
mediate for NPPC and GPC, and much greater for choline. 
To investigate whether the mutations introduced in the 
V,  CDR2  of T15  antibody  would  create  new  antigen 
binding specificities, the mutants were tested for their ability 
Discussion 
Effects of Random Mutations of H Chain CDR2 ofT15 Anti- 
body on PC Binding.  In this report, we have used a muta- 
genesis strategy that allowed rapid generation and isolation 
of random point mutants. Within the 57-nucleotide target 
sequence of the T15  V. CDR2, point mutations were in- 
troduced into every position and all 12 types of nucleotide 
substitutions were observed (data not shown). The distribu- 
tion of mutations was statistically random although some 
positions appeared to accumulate mutations more frequently 
than others. This approach has previously been used in other 
systems for structure-function analysis and has generated im- 
portant information not easily obtainable by other mutagen- 
esis procedures (41-44).  For example, Murray et al. (42) ap- 
plied this approach to the oll domain of a mouse MHC class 
I molecule and found that a mutation at conserved residue 
Tyr-27----Asp destroyed its recognition by alloreactive CTL; 
prior information had not implicated Tyr-27 as a critical res- 
idue for allorecognition. This strategy is particularly suit- 
able for antibody studies because the essentially random mu- 
tations generated by this technique provide a useful in vitro 
model system for examination of important aspects of anti- 
body somatic hypermutation. 
57% (26/46) of the mutant T15 antibodies either lost or 
had reduced binding to PC antigens. In contrast, none of 
the 46 mutants showed increased binding. The results  are 
consistent with previous findings showing that there is little 
affinity  maturation in the anti-PC response (45, 46) and that 
mutated T15 antibodies have less than optimal binding to 
S. pneumoniae (22).  Gearhart and colleagues (6, 46, 47) ex- 
amined the affinity of four IgG T15 antibodies with muta- 
tions  in  V.  and/or V~.  Three  of these  antibodies  had  a 
modestly increased affinity  (1.6-fold) for N-2,4-dinitrophenyl- 
p-aminophenyl-PC (DPPC), and one had no obvious change 
in affinity. Two were also tested for binding to PC, with one 
having no change and the other having a 3.3-fold decrease 
(47).  More recently, Levy et al.  (18) reported that T15  VH 
region genes isolated during the immune response to PC- 
KLH had a low level of mutation compared with other anti- 
body genes isolated during the same response.  Such results 
suggest that T15 antibodies may be particularly susceptible 
to binding loss or binding decrease due to somatic mutation. 
Our studies  here represent a direct test of the susceptibility 
of the T15 V. gene to functional damage by somatic muta- 
tion in CDR2 and, as such, the results provide support for 
the hypothesis. 
Recent studies from Foote and Milstein (48) suggest that 
association rates rather than affinity  provide the selection pres- 
sure in memory responses. Although few T15 antibodies dis- 
play increased affinity  during immune responses, some of them 
may have improved kinetics. It would be of great interest 
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association rates. 
In addition to mutations known to increase binding, mu- 
tations that do not affect binding or do not cause amino acid 
replacement (silent or nonselectable mutations) have also been 
frequently observed in secondary antibodies in various im- 
mune responses (49-51),  implying that somatic mutations 
may also generate mutants that no longer bind antigen. Based 
on the number of invariant and conserved residues compiled 
by Kabat et al.  (52), Shlomchik  et al.  (37) estimated  that 
half of the mutations in the framework regions would be 
deleterious. Others have analyzed the antibodies derived from 
particular immune responses and estimated that 25-50% of 
randomly acquired mutations would be damaging (17, 53). 
However, these calculations were based on the comparison 
of antibody sequences and represent only theoretical figures. 
Our finding that 43% of randomly mutated, unselected an- 
tibodies lost their antigen-binding ability provides the first 
direct evidence to support the prediction that many B cells 
in each mutating clone may be lost to the response. If one 
considers that ,,o40% of the CDR mutants may lose antigen 
binding ability, that 50% of the framework mutations could 
be structurally nonpermissive  (37),  and  that  ~5-10%  of 
random mutations can result in a termination codon (17, our 
data),  the wastage during the diversification of B cells via 
somatic mutation would be surprisingly high. However, as 
mentioned above, T15 antibodies are unique in that they com- 
pletely dominate the primary anti-PC response and have little 
affinity maturation. Thus, they may not be representative of 
the majority of antibody responses. The issue of  whether the 
frequent loss of  binding is a unique feature of T15 antibodies 
or if it is a common consequence of somatic mutation in other 
antibodies  is currently under investigation. 
Among the 15 single mutants, only one lost PC binding, 
indicating  that  in  T15  antibodies,  one  mutation  in  V, 
CDR.2 is tolerated well.  However,  two mutations sharply 
increased the frequency of  binding-loss mutants to 58%. This 
high frequency cannot be solely attributed to the higher prob- 
ability of hitting crucial positions; rather, in some cases, two 
or more mutations may have a cumulative effect (see  discus- 
sion below regarding M154). It is not clear at present why 
increasing the number of mutations to three or four did not 
further increase the fraction of nonbinding mutants. Some 
mutations may provide compensatory changes; or, the sample 
size in this instance may be too small to draw a conclusion. 
Experiments to assess the effects of individual as well as com- 
binations  of mutations are in progress. 
Do Vx CDR2 Mutations Generate New Specificities?  It was 
reported previously that a single mutation in V. CDR1 of 
the T15 antibody not only resulted in loss of binding to PC 
but also generated new specificities  for DNA, cardolipin, and 
some phosphorylated  proteins (11, 12). Other evidence also 
suggests that mutants with different antigen binding specifi- 
cities exist in the memory  response (9). Changes in fine speci- 
ficities after somatic mutations are known to occur in an- 
tiinfluenza HA responses (49, 54). Others have reported (37, 
38) that somatic mutations in antibodies  that bound only 
ssDNA gave them the added ability to bind dsDNA. Fur- 
thermore, Fish et al. (55) found that boosting with different 
analogues of arsonate elicited antibodies with different fine 
specificities. It has therefore been hypothesized that the so- 
matic mutation mechanism not only serves to increase the 
effciency  of the organism to deal with the eliciting antigen, 
but also may act as a means of increasing the overall diversity 
of the antibody repertoire (9). On the other hand, Malipiero 
et al. (6) analyzed the affinity of 12 mutated anti-PC anti- 
bodies (including the T15, McPC167, and McPC603 fami- 
lies) and found that eight had higher affinity than their un- 
mutated counterparts,  two had the same affinity, and two 
had lower afffnity. They therefore argued that the major role 
of somatic mutation was to increase affinity, not to create 
new spedficities. However, the polyreactivity of those mu- 
tants was not examined. To test this hypothesis, we exam- 
ined the 46 mutants for their reactivity to 11 PC-unrelated 
antigens,  including haptens, proteins,  and DNA. None of 
the mutants gained reactivity to these new antigens and few 
had obvious changes in fine specificities, consistent with the 
notion that the major effect of somatic mutation on anti- 
body function is to decrease or increase affinity for the pri- 
mary antigen rather than to generate new specificities. It is 
worth noting, however, that we selected the V~ CDR2 for 
mutational analysis because it is a central feature of the T15 
active site. We cannot exclude the possibility  that regions 
other than CDR2, if subjected to this type of analysis, would 
provide evidence for increased affinity and/or altered specifi- 
cities. 
Structural Basis  for Loss of  Binding in One- and Two-Site  Mu- 
tants.  Analysis of the known antibody structures (56, 57) 
shows that H chain CDR2 contains two adjacent antiparallel 
B strands connected by main-chain hydrogen bonds between 
residues 50 and 58 and between residues 52 and 56. The loop 
of residues 52A-54 connects the two strands at the top of 
the antigen binding pocket and varies in length and confor- 
mation. A second loop made up of residues 61-65 varies in 
sequence and conformation among the known structures and 
is distant from the antigen-binding site. The V. chain of the 
T15 antibody has very high homology to that of the related 
anti-PC antibody McPC603, differing by  just five  amino adds: 
four replacements and one insertion.  Because of this  high 
homology, the model of the binding site of the T15 anti- 
body (13) derived from the crystal structure of the antibody 
McPC603 (20) can be reliably used to examine the structural 
basis for loss of binding in our CDR2 mutants. The posi- 
tions of specific CDR2 residues are shown in the context 
of the V region structure and bound PC in Fig. 4. 
Our collection of a large number of CDR2 mutants pro- 
vides an excellent opportunity to investigate the contribu- 
tion of  individual residues to antigen binding. Although most 
of our mutants have  more than one amino acid substitution, 
those residues most responsible for the altered binding pheno- 
types can be estimated by subtractive comparisons.  For ex- 
ample, if a nonbinding antibody having two substitutions 
shares one with another antibody that retains binding, the 
shared mutation may not affect binding but the unique mu- 
861  Chen et al. Figure 4.  Computer graphics model of the T15 (S107) variable region 
(13). (A) Location of the V. CDR.2 residues critical for PC binding. The 
o~-carbon backbones for the V~ (blue,  right) and VL  (purple,  left) chains 
are shown with red CDR1 (H1 and L1), yellow CDK2 (H2 and L2), 
and green CDR3 (H3 and L3) o~-carbon  atoms  and hbds. Bound  PC (top, 
center) is shown as a ball-and-stick model color coded  by atom type with 
green carbon, blue nitrogen, red o~ygen, and yellow  phosphorus atoms. 
Critical residues are colored by atom type and have yellow labds with 
one-letter amino add codes. Ah-50 lies at the bottom of  the antigen  binding 
pocket adjacent to the important hydrogen  bond (green line) between  the 
hydroxyl  of  L chain Tyr-94  (green side  chain and label)  and the carboxylate 
group of H chain G1u-35 (red side chain and hbel). The side chains of 
Arg-52, Asn-52A, and Thr-56 extend  into the antigen binding site. Tyr-55 
lies between  the backbone  of V, CDR2 and the side  chains of framework 
residues Set-30, Arg-71, and Thr-73 (blue side chains and labels). Ala-61 
extends towards the VL chain, but is distant from the antigen-binding site. 
(B) Location  of  residues  that appear to be involved  in binding to the carbo- 
hydrate form of PC present in R36a; highly conserved  residues are also 
tation may be essential.  Fig.  5 lists several sets of mutants. 
Within each set, the residue estimated to be crucial for PC 
binding  is printed  in bold face and  underlined. 
In M22,  the Ala-50-*Thr  change is most likely respon- 
sible for the loss of antigen  binding.  The  other  mutation 
present in M22, Val-63-*Leu, is probably not critical because 
the three single-site mutants at Val-63, M67, M72, and M150, 
retain binding (Fig. 5). Even the nonconservative change of 
Val-63 to a negatively charged Glu in M150 does not appear 
to weaken PC binding. In addition, three multi-site mutants 
with mutations at Val-63 also retain binding:  M145, M159, 
and M205.  On the other  hand,  although  Ala-50 does not 
directly contact PC,  its side chain contacts  several residues 
known to be critical for PC binding. Ala-50 contacts the side 
chain of Arg-52,  the side chains  of H  chain Glu-35 and L 
chain Tyr 94, and the structurally conserved framework re- 
gion  of the  V.  chain  (Fig.  4  A).  The  Ala-50  side chain 
forms part of the surface upon which lie the side chain atoms 
of H chain Glu-35 and L chain Tyr 94 that make a hydrogen 
bond between the V. and VL chains.  This hydrogen bond 
appears to be important for maintaining the shape of the an- 
tigen binding pocket (20). Our results show that even a modest 
increase in the size of the residue 50 side chain (Ala-*Thr) 
can not be tolerated in this tightly packed region. The only 
other mutant with a change at position 50 is M260, which 
also has lost its ability to bind antigen, but this mutant has 
other changes that  may contribute  to the loss of binding. 
In the two-site mutants, M85 and M152, the Arg-52-*Ser 
and Arg-52-,.Ile changes are most likely responsible for the 
loss of antigen binding because of the importance of the salt 
bridge between the side chain of Arg-52 and the phosphate 
group of PC (20,  58).  In fact,  all  seven mutants  that  have 
a substitution at Arg-52 failed to bind PC. This is consistent 
with a recent mutagenesis study of the McPC603 antibody 
in which even the conservative Arg-52-*Lys exchange abol- 
ished PC binding (59). These results indicate that the precise 
geometry in this region is necessary for a favorable interac- 
tion between Arg-52 and the phosphate group of PC. Com- 
parison of the McPC603 structure with sequence data (58) 
and examination of the model of the T15 antibody (13) shows 
that  there are three charged side chains in the T15 binding 
site that electrostatically complement bound PC. Mutations 
of any one of these residues,  Arg  52,  Glu 35 (11),  or Asp 
95 (14) of the V,,  abolish binding.  These findings empha- 
size the importance of electrostatic interactions in binding PC. 
The only single-site mutant  that  has lost PC binding  is 
the Tyr-55-*Ser mutant  M66.  Inspection  of the  sequences 
compiled by Kabat et  al.  (52)  revealed that  Tyr-55 is very 
highly conserved in antibodies with V. CDR2 sequences of 
19 amino acids, which includes the T15 antibody. Tyr-55 has 
displayed. The side chains of residues Asn-52A and Asn-53 lie at the top 
of the binding pocket, extending into the antigen binding site, and may 
influence the binding of the large carbohydrate  carrier of R36a. Although 
residues Lys-52B  and Tyr-59 are highly conserved, they do not appear to 
be essential for antigen binding. Their side chains extend away  from the 
antigen binding site and lie on the surface of the antibody. 
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(~  A  S  B  N  K  A  N  O  X  T  T  E  Y  S  A  S  V  K  G  +  + 
~22  2  ...............  L  -  - 
M67  ................  F  -  -  +  + 
M72  ................  A  -  -  +  + 
MISO  ................  E  -  -  +  + 
M85  -  -  z  .....  ~  .......... 
MI60  ........  H  ....  R  .....  +  + 
M175  ........  H  S  .........  +  + 
M255  ....  Q  -  -  -  F  -  -  V  .....  M  -  +  + 
M152  -  -  S  ....  V  ........... 
M142  .......  V  ...........  +  + 
M66  ........  ~  .......... 
M/54  -  -  -  ~  .....  I  ......... 
M175  ........  H  S  .........  +  + 
M32  -  -  -  K  .........  R  .....  + 
MI60  ........  H  ....  R  .....  +  + 
M257  ......  K  Y  -  -  -  K  -  R  .....  +  + 
81229  -  G  ............  ~  .... 
M276  -  G  ...........  R  .....  +  + 
M296  -  I  .................  + 
MI07  ..............  G  ....  +  + 
Figure 5.  Comparison  of sequences of mutant antibodies showing 
residues critical for antigen  binding. Six sets of antibodies  are included. 
Each set has one nonbinding  antibody  that is compared  with one or more 
antibodies that retained  binding activity. The amino acid substitutions 
that may be responsible  for the altered binding  phenotypes  are indicated 
as bold face letters and underlined. 
been implicated as a key residue for maintaining the type 4 
canonical structure found for V. CDR2s that contain 19 
amino acids (56). The side chain of Tyr-55 does not contact 
PC in the McPC603 crystal structure. Instead, it points away 
from the antigen binding site, filling the region between the 
backbone atoms of CDR2 residues  52, 52a,  and 52b, and 
the V, framework region made up of residues Ser-30, Arg- 
71, and Thr-73 (Fig. 4 A). Thus, an appropriately sized res- 
idue may be essential for maintaining the proper geometry 
of the backbone of CDR2 by providing contacts between 
CDR2 and the V. region framework. Consistent with this, 
conservative replacements of Tyr-55 by the aromatic side chains 
of His  in  M160  and  M175  and  Phe  in  M255  did  not 
significantly affect binding (Fig.  5). 
The source of the loss of binding in the M154 mutant (Asn- 
52A-~Lys and Thr-56-~Ile) is not dear. Neither of these two 
residues directly contacts bound PC (20). The Asn-52A--*Lys 
mutation in M32 resulted in a lower binding for PC than 
seen for the T15 antibody and abolished R36a binding (Table 
1). Although M32 has a Ser-60--~Arg mutation, this change 
is probably not critical because two other antibodies (M160 
and M257) had the same mutation but retained full binding. 
The change of Thr56-*Ile also does not appear to be entirely 
responsible for loss of binding because M175 with Thr-56-~Ser 
retained full binding. In addition, a single-site mutant Thr- 
56--*Ile made by site-directed mutagenesis (M. Brown et al., 
Oregon Health Sciences  University, unpublished results) shows 
only a slightly reduced binding. Therefore, both changes may 
be required for loss of binding. 
The two-site mutant M229, with Ser-51~Gly and Ala- 
61-,.Pro, shares the Set-51 change with M276, which retains 
binding. Therefore, the loss of binding in M229 would ap- 
pear to be due to the Ala-61~Pro mutation. This result is 
unexpected because residue 61 is distant from the antigen- 
binding site (Fig. 4 A). Pro-61 is present in two antibodies 
with known structure, HyHED10 and J539 (21), which both 
show a very different conformation for the loop made up 
of residues 60-65 compared with the McPC603 antibody. 
This change in conformation, however, does not appear to 
perturb the structure of the region of V. CDR2 involved 
in antigen binding (residues 50-58), nor have residues 60-65 
been implicated as being important for contacts between the 
VL and V. chains in the McPC603 antibody (20).  It is in- 
teresting that Pro-61 does not occur in any of the V, CDP,2 
sequences of routine antibodies with 19 amino acid listed by 
Kabat et al. (52), although it frequently appears in CDR2s 
having 16 or 17 amino adds. Ala-61 can be replaced by other 
amino adds, as shown by the single-site mutant M107 with 
Ala-61~Gly, which does retain binding. This suggests that 
the conformational change of residues 60-65 induced by the 
conformationally  constrained Pro-61 side chain may be respon- 
sible for the loss of binding in M229, although the precise 
mechanism for this loss is not dear. 
These critical residues show a variety of different mecha- 
nisms for affecting antigen binding. Ala-50 and Arg-52 are 
essential for maintaining specific interactions between the an- 
tibody and PC, with even conservative  changes abolishing 
binding. Examination of the crystal structure of the related 
antibody McPC603 has suggested the importance of these 
two residues (20). Tyr-55 and Ala-61 are not in the binding 
pocket, but are important for maintaining the conformation 
of the V. chain CDR2 loop. Our mutagenesis experiments 
suggest the functional importance of these residues, which 
is not obvious from the crystal structure alone. In the double- 
mutant M154 with Asn-52A~Lys and Thr-56-~Ile, neither 
mutation alone is su~cient to cause loss of binding, but both 
mutations together do, suggesting an additive and/or cooper- 
ative effect between these two mutations. 
Several mutant antibodies (M32,  M106,  M135,  M173, 
M183,  and M289) lost or greatly reduced their binding to 
R36a while retaining considerable  binding to flee PC and 
PC-protein. This finding suggests that although these T15 
antibodies are PC specific, the actual ligand they recognize 
when PC is presented on a carrier  contains a contribution 
from the carrier itsels Indeed, Claflin et al. (60) have found 
that the consequence of an antibody response to PC in the 
context of S. pneuraoniae or Proteus morganii was determined 
by the carrier;  the former was dominated by T15 antibodies 
whereas the latter was dominated by the McPC603 family 
although both families of antibodies bind free PC. In Mcpc603 
antibodies, the region proposed to interact with P. morganii 
carrier determinants is on the surface area of the inner lip 
of the binding site, whereas the region contacting PC itself 
is at the bottom of the cavity and is preserved in all anti-PC- 
morganii antibodies (23, 24). Positions that are most impor- 
tant for differential  recognition of P. morganii include 52A 
and 53 of the V, CDR2 (22, 23). Interestingly, five of the 
six mutant antibodies (except M183) that differentially recog- 
nize R36a and PC-protein have a mutation at these positions 
(Fig.  5), which are on the inner lip of the binding cavity 
based on the computer derived model of T15 antibody (Fig. 
4 B). The Lys-52B~Glu change of M183 also occurs at the 
top surface of the V, CDR2. Although this residue extends 
away from the binding pocket, it might contact R36a car- 
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resulting in loss of binding to R36a. It will thus be of great 
interest to test whether our R36a nonbinding T15 mutants 
would bind P.  morganii and to characterize  the structural 
changes introduced by the corresponding CDR2 mutations. 
Mutations of Sequentially  Conserved Residues in VH CDR2. 
About 20% of the residues in antibody variable regions are 
invariant or susceptible mainly to conservative substitutions 
(52). It is assumed that such residues are important for main- 
taining the overall antibody structure rather than for deter- 
mining the binding spedficity (61). Nonconservative substi- 
tutions of such residues would thus result  in structurally 
nonfunctional antibody presumably due to improper folding 
and assembly or inability to be secreted. While most of these 
residues are located in framework regions, two of them, Tyr- 
59 and Lys-52B (Fig. 4 B), are found in the H chain CDR2. 
Among the total mouse Ig sequences compiled by Kabat et 
al.  (52), Tyr-59 has been found in 1,091/1,127 (97%) and 
Lys-52B in 165/171 (96%). Phenylalanine is the major sub- 
stitution for Tyr-59 and asparagine for Lys-52B. In addition, 
in the mouse V. subgroup IIIA to which V. $107 is as- 
signed,  Tyr-59 occurs in 137/138  and Lys-52B in 126/130 
reported sequences (52). Several  nonconservative substitutions 
were found at these residues in our 46 mutants. Serine (M164, 
183, and 241) and aspartic acid (M240) were able to substi- 
tute for Tyr-59 without affecting the overall structure of the 
antibody V region as assessed by their reactivity with an- 
tiidiotypic reagents (Table 1). Thus, loss of the spatial rela- 
tionships contributed by the bulky side chain of Tyr-59 does 
not appear to be an important consideration, although in the 
case of the serine substitution, this might be rationalized by 
the addition of a water molecule. Likewise, Lys-52B was sub- 
stituted by glutamic acid (M183), glutamine (M255),  and 
leucine (M260),  and the resultant  mutant clones were able 
to produce structurally functional antibody. Moreover, sev- 
eral of these antibodies (M183, M240, and M255) were also 
able to bind PC. These results neverthdess stress that substi- 
tution of highly conserved residues even by markedly different 
amino acids need not be deleterious to antibody structure. 
Although we do not formally exclude the possibility that 
other mutations elsewhere may compensate for the mutations 
at the conserved positions,  we consider this possibility un- 
likely because each of the seven  mutant antibodies has different 
substitutions  at different positions and it seems unlikely that 
each of these could compensate for the various substitutions 
at Tyr-59 or Lys-52B. In agreement with our results is the 
finding that replacement of two other invariant VH residues, 
Cys-92  and  Trp-36,  by  site-directed  mutagenesis  had  no 
influence on antibody function (62, 63). Thus, the significance 
of the invariant residues in the variable region needs to be 
interpreted carefully; they may be conserved for reasons other 
than maintaining the antibody structure, such as regulation 
of antibody repertoire development via idiotypic interactions 
or interactions with T cells; or they may play a role in signal 
transduction. 
In this report, we tested the hypothesis that T15 anti-PC 
antibodies are highly susceptible to loss of antigen binding 
upon somatic mutation. The finding that >55% of the T15 
antibodies with random mutations in their H chain CDR2 
lost or reduced their ability to bind PC whereas none had 
increased  binding activity supports this hypothesis. Although 
many mutations had a profound influence on antibody binding 
avidity, they did not create new binding specificities, neither 
did they change the overall conformation of the V region. 
Structural analysis on several of the nonbinding mutant anti- 
bodies revealed a variety of structural mechanisms underlying 
the loss of  binding. Some mutations directly affect  the antigen- 
antibody interaction while others may affect the conforma- 
tion of the CDR2 loop.  Thus, our examination  of a large 
number of mutants in a small region of the antibody com- 
bining site clarifies the roles of specific residues and provides 
fundamental information that will be useful for redesigning 
antibodies  (64,  65). 
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